期刊文献+

β受体阻滞剂在脓毒症及脓毒症休克中的应用研究进展 被引量:3

Research progress on the application ofβreceptor blocker in sepsis and septic shock
下载PDF
导出
摘要 脓毒症是一种全身炎性反应综合征,主要由感染引起的,进展及其迅速,早期未能控制感染,可迅速进展为脓毒症休克及多器官功能障碍而危及生命。脓毒症及脓毒症休克状态下可损伤心肌致心律失常,严重者可危及生命,β受体阻滞剂具有抗心率失常、抗炎及对心肌供氧平衡的作用,近来越来越多的目光转移至β受体阻滞剂运用于脓毒症及脓毒症休克的治疗。本文综述β受体阻滞剂的作用机制及其在脓毒症及脓毒症休克中的应用进展。 Sepsis is a systemic inflammatory response syndrome,mainly caused by infection,and progresses rapidly.Failure to control infection at early stage may rapidly progress to septic shock and multiple organ dysfunction,which may endanger life.In the state of sepsis and septic shock,it can damage the myocardia to result in arrhythmia,and even endanger life in severe cases.β-blockers have the effects of anti-arrhythmia,anti-inflammatory and regulating the oxygen supply balance of myocardium.Recently,much attention has been paid to the application ofβ-blockers in treatment of sepsis and septic shock.This article reviews the action mechanism ofβ-blockers and their application in sepsis and septic shock.
作者 吴颖越 李燕 WU Yingyue;LI Yan(2019 Master of Shanxi Medical University,Shanxi,Taiyuan 030000,China)
出处 《河北医药》 CAS 2022年第24期3807-3811,共5页 Hebei Medical Journal
关键词 脓毒症 脓毒症休克 Β受体阻滞剂 兰地洛尔 艾司洛尔 sepsis septic shock beta blocker landiolol esmolol
  • 相关文献

参考文献15

二级参考文献112

  • 1王永清,樊寻梅.脓毒症及感染性休克时心肌抑制的炎症介质机制[J].小儿急救医学,2005,12(2):151-153. 被引量:20
  • 2林丽丽,陈锡明.序贯器官衰竭评估[J].青岛医药卫生,2006,38(1):63-65. 被引量:3
  • 3Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States : analysis of incidence, outcome, and associated costs of care [J]. Crit Care Med, 2001,29 (7) : 1303-1310.
  • 4Lever A, Mackenzie I. Sepsis: definition, epidemiology, and diagnosis [J]. BMJ, 2007, 335 (7625):879-883.
  • 5Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000 [J]. N Engl J Med, 2003, 348 (16) :1546-1554.
  • 6Yealy DM, Kellum JA, Huang DT, et al. A randomized trial of protocol-based care for early septic shock[J]. N Engl J Med, 2014, 370 ( 18 ) : 1683-1693.
  • 7Hamzaoui O, Teboul J, Teboul L. The role of beta-blockers in septic patients [ J]. Minerva Anestesiol, 2015, 81 (3) : 312- 319.
  • 8Morelli A, Donati A, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock:a randomized clinical trial [J]. JAMA, 2013, 310 ( 16 ) : 1683-1691.
  • 9Wang ZG, Wu QH, Nie XB, et al. Combination therapy with milrinone and esmolol for heart protection in patients with severe sepsis: a prospective, randomized trial [ J ]. Clin Drug Investig, 2015,35( 11 ) :707-716.
  • 10Gore DC, Wolfe RR. Hemodynamic and metabolic effects of selective betal adrenergic blockade during sepsis [ J ]. Surgery, 2006, 139 (5) :686-694.

共引文献82

同被引文献50

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部